Atopic Dermatitis

Pharmacists can play a critical role in this therapy, panelists in a recent Pharmacy Times® Peer Exchange say.

If approved, Dipilumab will be the first biologic medicine available in the United States to treat uncontrolled moderate-to-severe AD for patients aged 6 months to 5 years.

Tralokinumab-ldrm is an interleukin-13 antagonist recently approved for the treatment of moderate-to-severe atopic dermatitis.

The 2 drugs are the first small molecule JAK-1 inhibitors to be approved in the United States as treatment options for patients who are not responding to other therapies.

Future studies are necessary to continue evaluating the true benefits of dupilumab in conditions like atopic dermatitis.

Across the trials, abrocitinib demonstrated a consistent safety profile and profound improvements in skin clearance, extent of disease, and severity.

It is important for pharmacists to know the latest updates on the right treatment options for atopic dermatitis.

Dupilumab has been a breakthrough treatment for patients with atopic dermatitis, but future studies are needed to continue learning about its strength.

Eli Lilly says the drug in combination with TCS also achieved all key secondary endpoints versus the placebo for individuals with AD.